drugset / Trial / NCT06335407
Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study
Phase 1
Recruiting
10 enrolled
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
BioXcel Therapeutics Inc · collabCongressionally Directed Medical Research Programs · collabRTI International · collabUnited States Department of Defense · collabVA Connecticut Healthcare System · collabYale University · collab
NaSequentialOpen-labelOther
Summary
The overall objective of the proposed study is to determine if Dexmedetomidine HCl (BXCL501) is safe for treatment of alcohol use disorder (AUD) with comorbid posttraumatic stress disorder (PTSD) in an outpatient setting and also shows potential signals of efficacy thereby supporting the conduct of later phase clinical trials.
Timeline
- Start
- 2025-07-28
- Primary completion
- 2026-03-30
- Completion
- 2026-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexmedetomidine | Other / unclassified | 80 ug | Oral |